**California voters face Proposition 38 on the November 3, 2026 ballot, an initiative statute authorizing $8.4 billion in general obligation bonds for immunology and immunotherapy research.** The measure would allocate half the proceeds to a single University of California-affiliated nonprofit institute selected by the Department of Public Health and the other half through grants to public and nonprofit institutions, with at least half directed to cancer, heart disease, and Alzheimer’s research. It includes requirements for 20% below-average pricing on resulting therapies in California and a 10% revenue return to offset costs. Trader consensus favoring rejection at 58% reflects concerns over the $500–600 million annual General Fund repayment burden for roughly 20 years, the earmarked structure benefiting a specific UCLA-linked entity with substantial prior private philanthropic backing, and limited organized support amid broader fiscal scrutiny of new state debt. Recent reporting has highlighted these allocation and accountability issues as key points of debate ahead of the election.